Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun biochemistry Any of a class of
proteins that bind tociclosporin
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word cyclophilin.
Examples
-
a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease.
-
A NMR structure determination of the cyclophilin A-cyclosporin A complex was pursued as a joint project with two former graduate students,
-
They had a homozygous start-codon mutation in the peptidyl-prolyl isomerase B gene (PPIB), which results in a lack of cyclophilin
-
Debio 025 (alisporivir), a selective, first-in-class cyclophilin
-
They had a homozygous start-codon mutation in the peptidyl-prolyl isomerase B gene (PPIB), which results in a lack of cyclophilin
-
They had a homozygous start-codon mutation in the peptidyl-prolyl isomerase B gene (PPIB), which results in a lack of cyclophilin
-
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect.
THE MEDICAL NEWS Editors 2010
-
Lausanne (ots) - Debiopharm Group [TM] (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus
Presseportal redaktion@presseportal.ch 2010
-
They had a homozygous start-codon mutation in the peptidyl-prolyl isomerase B gene (PPIB), which results in a lack of cyclophilin
-
Research shows that cyclophilin inhibitors have neuroprotective effects which open broad therapeutic areas of completely unmet medical need to Isotechnika such as USPTO issues two new patents for EKR Therapeutics 'RTU Cardene I.V. Premixed Injection
THE MEDICAL NEWS Editors 2010
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.